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Sevelamer attenuates the progression of coronary and aortic In the year 2000, there were approximately 280,000
calcification in hemodialysis patients. patients undergoing dialysis for end-stage renal disease
Background. Cardiovascular disease is frequent and severe
(ESRD) in the United States [1]. The annual mortalityin patients with end-stage renal disease. Disorders of mineral
rate in dialysis patients is in excess of 20%, and cardiovas-metabolism may contribute by promoting cardiovascular cal-
cification. cular mortality rates are on average 30-fold higher than
Methods. We conducted a randomized clinical trial compar- in the general population with especially high rates among
ing sevelamer, a non-absorbed polymer, with calcium-based phos-
younger individuals [2]. Several factors have been pro-phate binders in 200 hemodialysis patients. Study outcomes
posed to contribute to the exceptionally high rate ofincluded the targeted concentrations of serum phosphorus, cal-
cium, and intact parathyroid hormone (PTH), and calcification cardiovascular disease in ESRD, including the adverse
of the coronary arteries and thoracic aorta using a calcification hemodynamic effects of dialysis, oxidative stress, inflam-
score derived from electron beam tomography.
mation, hypertension, hyperhomocysteinemia, and theResults. Sevelamer and calcium provided equivalent control
relatively infrequent use of aspirin, lipid-lowering agents,of serum phosphorus (end-of-study values 5.1  1.2 and 5.1 
1.4 mg/dL, respectively, P  0.33). Serum calcium concentra- and beta-adrenergic antagonists [3–7]. Disorders of min-
tion was significantly higher in the calcium-treated group (P  eral metabolism (principally hyperphosphatemia, hyper-0.002), and hypercalcemia was more common (16% vs. 5%
calcemia, and hyperparathyroidism) have also been pro-with sevelamer, P  0.04). More subjects in the calcium group
had end-of-study intact PTH below the target of 150 to 300 posed to play a role [8]. Epidemiological studies have
pg/mL (57% vs. 30%, P  0.001). At study completion, the shown a direct correlation between serum phosphorus and
median absolute calcium score in the coronary arteries and
the calcium-phosphorus product and mortality in hemo-aorta increased significantly in the calcium treated subjects but
dialysis patients [9, 10]. Recently, Goodman et al showednot in the sevelamer-treated subjects (coronary arteries 36.6
vs. 0, P  0.03 and aorta 75.1 vs. 0, P  0.01, respectively). a striking degree of coronary artery calcification in young
The median percent change in coronary artery (25% vs. 6%, adults with ESRD, using electron beam tomographyP  0.02) and aortic (28% vs. 5%, P  0.02) calcium score
(EBT) [11]. In that study, the calcium-phosphorus productalso was significantly greater with calcium than with sevelamer.
Conclusions. Compared with calcium-based phosphate bind- and the dose of oral calcium ingested were significantly
ers, sevelamer is less likely to cause hypercalcemia, low levels associated with the likelihood of coronary calcification.
of PTH, and progressive coronary and aortic calcification in
Based on these findings, we hypothesized that seve-hemodialysis patients.
lamer, a non-absorbed, non-calcium-containing polymer,
would be less likely to lead to progressive cardiovascular1 The Treat to Goal Working Group members include (United States)
calcification than calcium-based phosphate binders.G.M. Chertow and G. Caputo (San Francisco, CA); P. Raggi (New
Orleans, LA); G. Schulman (Nashville, TN); A. Kuhlik, M. Derman
and M. Clouse (Boston, MA); J.T. McCarthy and J. Breen (Rochester,
MN); J. Silberzweig and J. Markisz (New York, NY); W. Goodman METHODS
and J. Goldin (Los Angeles, CA); R. Toto and M. Boyce (Dallas,
Texas); (Germany) J. Bommer (Heidelberg); H.H. Neumayer, R. Subjects
Krause, G. Asmus and B. Hamm (Berlin); R. Brunkhors (Hannover);
Subjects were adult (age 19 years) maintenance he-D.H.W. Gro¨nemeyer (Bochum); W. Schulz (Bamberg); J. Braun (Nu¨rn-
berg); M. Georgi (Mannheim); S. Achenbach and W. Moshage (Er- modialysis patients enrolled at 15 participating dialysis
langen); and (Austria) H. Holzer and R. Rienmu¨ller (Graz). units: seven in the US, seven in Germany, and one in
Austria. Patients with the following medical conditionsKey words: randomized clinical trial, cardiovascular calcification; end-
stage renal disease, mineral metabolism, hypercalcemia. were excluded from participation: serious gastrointes-
tinal disease (including dysphagia, active untreated gas- 2002 by the International Society of Nephrology
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troparesis, severe motility disorder, major intestinal sur- calcium was adjusted for the serum albumin concentra-
tion using the formula: adjusted Ca  total measuredgery, markedly irregular bowel function), ethanol or drug
dependence or abuse, active malignancy, HIV infection, calcium 0.8 ( 4.0 g/dL albumin). Subjects could use
aluminum as a rescue binder if the calcium-phosphorusvasculitis, or whose diabetes mellitus or hypertension
were so poorly controlled as to interfere with the conduct product exceeded 72 mg2/dL2. After 12 weeks, the dose
of phosphate binder, vitamin D (1,25-dihydroxy vitaminof the study as deemed by the investigator.
Written informed consent was obtained from all sub- D3, or synthetic analog, IV or PO, per the investigator),
and the dialysate calcium concentration could be titratedjects. The study was conducted in compliance with the
Declaration of Helsinki and Committees on Human Re- every four weeks to achieve serum phosphorus and cal-
cium levels in the aforementioned target ranges and asearch at each of the participating Universities and dial-
ysis units. target range for intact parathyroid hormone (PTH) of
150 to 300 pg/mL. This range was chosen a priori based
Study design and procedures on expert opinion, with the rationale that intact PTH val-
ues in excess of 300 pg/mL were more likely to be as-Power analysis. We hypothesized that a difference of
10 mg2/dL2 in the calcium-phosphorus product would sociated with increased bone remodeling and osteitis
fibrosa cystica, while intact PTH values 150 pg/mLbe achievable and significant (assuming a change of 35
mg2/dL2 in the sevelamer group versus 25 mg2/dL2 in the were more likely to be associated with an abnormally
low state of bone remodeling in ESRD patients [12].calcium group). To calculate a target sample size, we
considered a two-group t test with a two-sided alpha Serum phosphorous and calcium were drawn weekly
during the titration phase and monthly thereafter. In-error rate of 5% and a common standard deviation of
20 mg2/dL2 based on previous trial experience. We esti- tact PTH was drawn at screening, baseline, 12 weeks
and monthly thereafter. Total cholesterol, low densitymated that 200 patients would provide 90% power of
detecting a significant difference if one existed. The stan- lipoprotein (LDL)-cholesterol, high density lipoprotein
(HDL)-cholesterol, and triglycerides were drawn atdard deviation of change in EBT score in ESRD patients
was unknown and, therefore, we could not predict whe- baseline, 12 weeks, 24 weeks, and 52 weeks. LDL was
calculated according to the Friedewald formula on non-ther the chosen sample size would be sufficient to detect
a difference in EBT scores. fasting samples [13, 14]. All blood samples were analyzed
at Quest Diagnostics (Van Nuys, CA, USA and Heston,Washout (run-in) phase. After screening, subjects un-
derwent a two-week washout period in which all phos- Middlesex, UK). These laboratories used the same stan-
dardized assays.phate binders were withheld (weeks 2 to 0). Subjects
who developed hyperphosphatemia (serum phosphorous Imaging procedures. Subjects underwent an EBT im-
aging procedure at days 0 and at 26 and 52 weeks. EBT5.5 mg/dL) during the washout period were eligible
for randomization. imaging procedures were performed on C-150 scanners
(GE-Imatron, South San Francisco, CA, USA) with aRandomization. Patients were randomized in a 1:1
ratio to receive either sevelamer or calcium, stratified 100-msec scanning time and a single-slice thickness of
three millimeters. Thirty-six to 40 tomographic slicesby site and the presence of diabetes at screening. The
randomization schedule was computer generated using were obtained for each subject during a single breath-
holding period. Tomographic imaging was electrocardio-SAS 6.12 (Cary, NC, USA).
Treatment phase. Subjects were randomized to seve- graphically triggered at 60 or 80% of the R-R interval
(according to each individual imaging center’s protocol)lamer (Renagel 800 mg tablets; GelTex Pharmaceuti-
cals, Waltham, MA, USA) or calcium-based binders. and proceeded from the level of the carina to the dia-
phragm. Thus, this imaging protocol prevented the visu-Subjects treated with calcium in the US received calcium
acetate (PhosLo 667 mg tablets; Braintree Pharmaceu- alization of a portion of the aortic arch. All areas of
calcification with a minimal density of 130 Hounsefieldticals, Inc., Braintree, MA, USA) and subjects in Europe
were treated with calcium carbonate (Sertuerner 500 units (HU) within the borders of the coronary arteries,
aorta, mitral valve, and aortic valve were computed. Amg tablets; Sertuerner Arzneimittel GmbH, Guetersloh,
Germany). Due to the size, appearance, and taste of the calcified plaque was considered present if at least three
contiguous pixels with a density of 130 HU were de-tablets, neither the subjects nor the investigators were
blinded to the treatment regimen. Adherence to treat- tected (an area equivalent to 1.03 mm2).
The acquired images were reviewed on a NetraMDment was estimated by pill counts.
The treatment phase lasted 52 weeks. During the first workstation (ScImage, Los Altos, CA, USA). The total
volume and density of calcification were derived for the12 weeks, the dose of phosphate binder was titrated
every three weeks to achieve serum phosphorous and coronary arteries and aorta, mitral valve, and aortic
valve. The traditional calcium score originally describedcalcium concentrations in the target ranges of 3.0 to
5.0 mg/dL and 8.5 to 10.5 mg/dL, respectively. Serum by Agatston et al [15] and an interpolated volume score
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Table 1. Baseline characteristics of study subjectswere calculated [16–18]. The Agatston score is obtained
by multiplying the area of a calcified focus by a weighted Sevelamer Calcium
(N  99) (N  101) P valuedensity coefficient based on the peak density of the calci-
Age years (mean  SD) 5714 5616 0.88fication [15]. The purpose of EBT imaging in our study
Sex % female 36% 34% 0.77was to investigate whether the treatments would contrib-
Race
ute differently to calcium deposition in the arterial wall. Black 17% 23% 0.34
White 71% 66%Since the Agatston score is very sensitive to density, and
Other 12% 11%density is directly related to the calcium content of the
Diabetes % 32% 33% 1.0
palque, this was considered the primary EBT end-point. Hypertension % 86% 83% 0.70
Smoker % 3% 8% 0.21The volumetric scoring method does not apply a scalar
Primary Cause of ESRD %density factor but rather estimates the bulk of atheroscle-
Hypertension 16% 17% 0.66
rosis [16], and was calculated for completeness. The me- Glomerulonephritis 26% 16%
Diabetes 23% 28%dian inter-scan variability is 8 to 10% for the Agatston
Polycystic kidney disease 9% 11%score [17, 18] and 6 to 8% for the volume score [16].
Other 26% 28%
Scans were considered of acceptable research quality Dialysis vintage years, median 3.6 2.9 0.24
Phosphate binder use prior toonly if the images were free from artifacts due to motion,
study entry % 0.81respiration, or asynchronous electrocardiographic trig-
Calcium carbonate 38% 44%
gering. To ensure the continuity and consistency of the Calcium acetate 33% 36%
Calcium  aluminum 14% 13%calcium score interpretation, a single expert investigator
Sevelamer 3% 1%(PR) unaware of the patients’ clinical status and treat-
Other combinations 12% 6%
ment reviewed all EBT scans. However, a second re- Vitamin D usage at study entry % 56% 59% 0.67
viewer analyzed a random sample of 10% of all the scans.
The inter-rater agreement was 100% for the presence
or absence of calcification, and 90% of total scores
were within 15% of each other for the two reviewers. groups were compared with the Wilcoxon signed rank
test. Between groups comparisons were performed usingFor descriptive purposes, subjects were classified into
four coronary calcification groups: none (calcium score the Fisher exact test for categorical variables and the
Wilcoxon rank sum test for continuous variables.0), mild to moderate (calcium score  1 to 400), severe
(calcium score  401 to 1000), and very severe (calcium Evaluation of the change in calcification was per-
formed in several ways owing to imperfections of eachscore 1000). This classification is a modification of the
categorization proposed by Rumberger et al [19]. Cal- approach. The first method was calculation of the abso-
lute change in calcification score (26- or 52-week valuecium scores 400 indicate severe and extensive athero-
sclerotic disease. Non-uremic patients with calcification minus baseline value). While simple, this approach weighs
more heavily those subjects with extensive baseline calci-scores in this range are very likely to have obstructive
coronary artery disease (CAD), with a high risk of devel- fication who are more likely to experience larger nominal
changes in calcification (in either direction) [18]. Theoping symptomatic myocardial ischemia [19]. For this
study, the classification was modified to accommodate relative (percent) change in calcification score was also
calculated. While easy to interpret, this approach runsthe more extensive degree of calcification observed in
the hemodialysis population. Therefore, the mild and the risk of weighing more heavily those subjects with
less extensive baseline calcification [18]. For example, amoderate categories were combined into a single cate-
gory. Additionally, a fourth group, “very severe,” was subject who experienced an increase in calcification score
from 10 to 20 (100%) would be considered to have in-introduced to categorize those subjects with markedly
elevated calcium scores. There is no published classifica- creased his or her calcification burden more than a sub-
ject whose score increased from 500 to 900 (80%). Totion scheme for aortic calcification scores. Therefore, we
divided subjects into a group without aortic calcification avoid extreme percent increases among individuals with
little or no baseline calcification, we excluded subjectsand further divided the remaining subjects with calcifica-
tion into tertiles. with baseline calcification scores below 30 in the relative
change analyses as done in a prior study [20]. We re-
Statistical analysis solved to report absolute and relative effects of the study
treatments on calcification, recognizing that qualitativelyPretreatment characteristics were compared between
the sevelamer and calcium groups using the Fisher exact and quantitatively consistent results in both analyses
would be required for our conclusions to be robust. Totest for categorical variables and the Wilcoxon rank sum
test for continuous variables. All laboratory analyses determine the effect of baseline calcification on subse-
quent calcification, we used mixed model regression onwere performed using a last value carried forward ap-
proach. Changes from baseline to end-of-study within ranked changes of coronary artery and aortic calcifica-
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Table 2. Main biochemical results at study completion
Sevelamer (N  99) Calcium (N  101)
Baseline Final Baseline Final P value
Phosphorus mg/dL 7.61.8 5.11.2 7.41.9 5.11.4 0.33
Calcium mg/dL 9.40.7 9.50.6 9.30.7 9.70.7 0.002
Hypercalcemia % 3% 5% 1% 16% 0.04
Calcium-phosphorus
product mg2/dL2 7117 4812 6918 4914 0.12
Intact PTH pg/mL 232 224 200 138 0.11
Total-C mg/dL 18136 14128 18447 18249 0.0001
LDL-C mg/dL 10230 6521 10237 10343 0.0001
HDL-C mg/dL 4413 4310 4615 4512 0.16
Triglycerides mg/dL 148 137 139 150 0.22
Hypercalcemia was defined as calcium adjusted for albumin 10.5 mg/dL. Abbreviations are: PTH, parathyroid hormone; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol. Baseline values were established after two-week washout from previous phosphate binder. Values expressed
as mean  SD, except median for intact PTH and triglycerides. P value for Wilcoxon rank sum test comparing change from baseline across treatment groups. Final
values are last values carried forward for subjects who dropped out.
Table 4. Absolute change from baseline calcification scoresTable 3. Baseline electron beam tomography (EBT) scores
Sevelamer Calcium P value Between
group
Coronary Sevelamer Calcium P value
N 92 94 0.51
Mean  SD 17122901 11251583 Coronary arteries at 26 weeks
N 66 75Median (interquartile
range) 683 (78;2226) 600 (86;1413) Mean  SD 134697 110413 0.002
Median (interquartileAorta
N 92 94 0.39 range) 0 (124; 53) 56 (0; 206)
Within-group P value 0.51 0.0001Mean  SD 38746474 32337644
Median (interquartile Coronary arteries at 52 weeks
N 62 70range) 746 (35;4672) 367 (6;3527)
Mean  SD 46692 151471 0.04P value refers to Wilcoxon rank sum test for comparison between groups.
Median (interquartileSeven subjects in each group did not undergo EBT testing at baseline.
range) 0 (33; 174) 37 (0; 330)
Within-group P value 0.67 0.0002
Aorta at 26 weeks
N 66 75
Mean  SD 5951723 2301697 0.03tion, with baseline calcification and other predictors of
Median (interquartile
calcification severity as covariates. range) 0 (201; 90) 11 (3; 201)
Within-group P value 0.27 0.02All probability values are two-tailed. P values 0.05
Aorta at 52 weekswere considered statistically significant. All analyses were
N 62 70
conducted using SAS 6.12 (Cary, NC, USA), with the Mean  SD 5321706 1853100 0.01
Median (interquartileexception of the regression analysis that was conducted
range) 0 (258; 158) 75 (0; 441)using SAS 8.0.
Within-group P value 0.43 0.0007
N denotes the number of individuals who remained active in the study after
undergoing baseline EBT testing (Table 3). Within-group comparisons were
RESULTS made with Wilcoxon signed rank test, between group comparisons with Wilcoxon
rank sum test. Corresponding P values for coronary artery volume scores wereStudy subjects 0.08 at week 26 and 0.31 at week 52. Corresponding P values for aortic volume
scores were 0.12 at week 26 and 0.45 at week 52.Randomization began on May 26, 1999 and ended on
January 19, 2000. The last subject completed the study
on January 25, 2001. Baseline characteristics of study
subjects are summarized in Table 1. Adherence to the ate in Europe was 3.9 g (equivalent to 8 Sertuerner
prescribed dose was 86% in the sevelamer group and 500 mg tablets).
80% in the calcium group (P 0.03). Sevelamer subjects
Biochemical end pointsingested an average of 6.5  2.9 g of binder per day
(equivalent to 8 Renagel 800 mg tablets) compared Table 2 summarizes the key biochemical end points.
with calcium subjects who ingested an average dose of Baseline values represent laboratory test results ob-
4.3  1.9 g per day. The average dose of calcium acetate tained after a two-week phosphate binder-free washout
in the United States was 4.6 g (equivalent to7 PhosLo period. Over the course of the study, 17% of sevelamer
subjects and 43% of calcium subjects experienced at least667 mg tablets) and the average dose of calcium carbon-
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one hypercalcemic episode (P  0.0005). Suppression of
intact PTH below the 150 to 300 pg/mL target range was
more common at the end of the study in the calcium
group (57 vs. 30%, P  0.001) despite the protocol-
specified reduction or cessation of vitamin D for intact
PTH below 150 pg/mL. Indeed, over the maintenance
phase of treatment, vitamin D usage (expressed as an
equivalent dose of 1,25-dihydroxy vitamin D3) decreased
by approximately 0.25 	g/week in the calcium-treated
subjects and increased by approximately 0.25 	g/week
in the sevelamer-treated subjects. Twelve percent of sub-
jects in the calcium group required rescue aluminum for
a calcium-phosphorus product 72 mg2/dL2 compared
with 4% of subjects on sevelamer (P  0.07). LDL cho-
lesterol declined substantially for the sevelamer group
(mean 37 20%, P 0.0001) but not the calcium treated
group as expected per prior experience [21].
The effects of calcium and sevelamer on biochemical
end points were consistent across study sites (US vs.
Europe) and were not significantly influenced by age,
gender, race, diabetes, or baseline vitamin D prescription
(data not shown).
Cardiovascular calcification
At baseline, EBT detected coronary artery calcifica-
tion in 83% and aortic calcification in 80% of study sub-
jects. Mitral valve calcification was observed in 46% and
aortic valve calcification in 35% of study subjects. Table 3
summarizes the baseline EBT scores for coronary arter-
ies and aorta. Of the 200 randomized patients 14 did not Fig. 1. (A) Median percentage change in coronary artery calcification
undergo EBT imaging. Therefore, the data in Table 3 scores from baseline to week 26 and week 52 in patients with calcification
(scores 30) at baseline. *Indicates within-treatment, P  0.001. Com-are based on an initial imaging cohort of 186 patients.
parisons between calcium-treated ( ) and sevelamer-treated ()
groups, P  0.01 at week 26 and P  0.02 at week 52. CorrespondingAbsolute changes in calcification score values for volume score were 9% versus 18% (P  0.02) for sevelamer
and calcium at week 26, respectively, and 10% versus 28% (P 0.04) forAbsolute changes in calcification scores in the two
sevelamer and calcium at week 52, respectively. (B) Median percentagetreatment groups are summarized in Table 4. change in aortic calcification scores from baseline to week 26 and week
There was significant progression of coronary artery 52 in patients with calcification (scores 30) at baseline. *Indicates
within treatment, P  0.001. Comparisons between calcium- and seve-and aortic calcification in the calcium group at both time
lamer-treated groups, P  0.01 at week 26 and P  0.02 at week 52.points (mean and median scores positive), and no sig- Corresponding values for volume score were 10% versus 23% (P 
nificant progression in the sevelamer group (mean scores 0.02) for sevelamer and calcium at week 26, respectively, and 22% versus
37% (P  0.05) for sevelamer and calcium at week 52, respectively.negative, median scores zero). All comparisons between
groups were statistically significant. Mitral valve and
aortic valve scores did not change significantly in either
group (data not shown).
while the relative score changes for sevelamer treated
subjects were not. For the sevelamer treated subjects theRelative change in calcification score
median (interquartile range) percent changes at 52 weeksOf the 25 subjects with no coronary calcification at
for the coronary arteries and aorta were 6% (14 tobaseline, 20 continued to have no calcification on repeat
24%) and 5% (21 to 39%), respectively. For the cal-scans. Similarly, of the 32 subjects with no aortic calcifi-
cium treated patients the median (interquartile range)cation at baseline, 27 continued to have no calcification
percent changes at 52 weeks were 25% (5 to 63%) andon repeat scans. These subjects were excluded from anal-
28% (3 to 79%) for the coronary arteries and aorta,yses of relative change (Methods section). Figure 1 shows
respectively.the relative increase in coronary artery and aortic calcifi-
The between treatment comparisons were statisticallycation at 26 and 52 weeks. The relative changes measured
in calcium treated subjects were statistically significant significant (see Fig. 1 legend). Figure 2 shows an example
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Fig. 2. Comparison of axial electron beam tomography (EBT) sections of the heart of a patient treated with sevelamer. The 52-week scan (right
panel) shows a smaller total coronary artery calcium score than the initial scan (left panel). The computer software automatically assigns a color
code to each plaque based on its density with a transition from various shades of red to blue as density increases. In this case the delayed scan
demonstrates a less dense plaque in the middle of the right coronary artery (white arrows).
of comparative EBT scans in a patient treated with seve- DISCUSSION
lamer. In this study, 200 hemodialysis subjects were random-
ized to receive either sevelamer or calcium salts for treat-
Effect of baseline calcification and other factors ment of hyperphosphatemia. The control of serum phos-
The degree of baseline calcification was directly corre- phorus was equivalent with both agents, although subjects
lated with the likelihood and degree of absolute progres- randomized to calcium experienced significantly more
sion over time. The between group differences in calcifi- hypercalcemia and intact PTH levels below the targeted
cation were amplified in subjects with more severe range. Furthermore, both coronary artery and aortic cal-
baseline calcification of coronary arteries and aorta (P cification progressed significantly with calcium but not
0.03 and P  0.04 for the interaction, respectively). This with sevelamer. The difference was detectable as early as
was observed with both the Agatston score and the vol- six months and continued to be significant at one year.
ume score (P  0.01 and P  0.27). Figure 3 illustrates Calcium was initially thought to be especially effective
the progression of coronary artery and aortic volume in patients with ESRD, not only because of its efficacy
scores by baseline severity groupings. as a phosphate binder, but also because of its direct effect
(via normalizing or raising above normal the level of
Safety serum calcium) on secondary hyperparathyroidism and
In general all binders were well tolerated. Routine associated high turnover bone disease. However, recent
biochemical safety parameters were similar between the evidence suggests that the use of high-dose calcium salts
treatment groups except for serum bicarbonate, which in ESRD might not be as benign as previously suspected
was higher in the calcium treated subjects (22.1  4.4 [11]. Sevelamer is a nonabsorbed polymer (calcium and
mEq/L vs. 19.2  4.3 mEq/L, P  0.0003) as the calcium metal free) that has proved to be an effective phosphate
salts provide base and sevelamer does not. There were binder [21, 22]. It also acts as a bile acid sequestrant and
six deaths in the sevelamer group and five deaths in the is therefore capable of reducing LDL cholesterol levels
calcium group. A total of 37 subjects on sevelamer were [21]. In an open label study sevelamer taken alone led
hospitalized compared with 48 subjects on calcium (P  to a gradual increase in intact PTH. Thus, a combination
0.15). Sevelamer-treated subjects were hospitalized for of sevelamer and vitamin D metabolites may be required
at total of 567 days compared with 980 days for the to optimize control of hyperparathyroidism [23].
Vascular calcification is strongly associated with an in-calcium-treated subjects (P  0.23).
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which the progression of calcification over time has been
influenced by any means.
A possible mechanism explaining the observed treat-
ment effects may be ongoing calcium loading related to
oral calcium ingestion. This would be consistent with the
findings of Goodman et al and Gue´rin et al, who reported
an association of the dose of oral calcium and the risk of
vascular calcification [11, 36]. Notably, the serum calcium
may not reflect the total body calcium load, and excess
calcium may be particularly prone to deposit in the tis-
sues when the serum phosphorus is high and when the
intact PTH is low, the latter reflecting a state of low
bone turnover [12]. Other factors unrelated to calcium,
such as the favorable effect of sevelamer on LDL choles-
terol, also may have contributed to the study’s findings.
In a cross sectional analysis of these study subjects, we
found serum phosphorous, calcium, and intact PTH to be
related to coronary and aortic calcification, while total,
LDL, and HDL cholesterol were not [8]. Callister et al
demonstrated that HMG Co-A reductase inhibitors re-
duce or arrest the progression of coronary artery cal-
cification in persons with normal renal function [20].
Whether statins would reduce coronary and aortic calci-
fication in persons with ESRD is unknown.
Limitations of the study include the relatively brief
period of observation (1 year), the absence of subjects
on peritoneal dialysis, and the inability of EBT to distin-
guish between intimal (atherosclerotic) and medial calci-
fication, although both carry a negative prognosis for
cardiovascular events. While both treatments were able
to achieve excellent control of serum phosphorus and
calcium-phosphorus product, the study failed to achieve
the end point for which it was powered (a 10 mg2/dL2
difference in end-of-study calcium-phosphorus productFig. 3. (A) Nominal change in coronary artery coronary artery volume
scores from baseline to week 52 by baseline calcification group. (B) between study groups). Nevertheless, the calcium-phos-
Nominal change in aorta volume scores from baseline to week 52 by phorus product was marginally lower in the sevelamerbaseline calcification group. Symbols are: () sevelamer; ( ) calcium.
group and the serum calcium and intact PTH levels were
more likely within target ranges. Finally, we cannot de-
termine the exact mechanism of the relative protection
afforded by sevelamer. Additional studies will be requiredcreased risk of cardiovascular events and mortality in both
to determine whether reduced calcium intake, fewer epi-non-uremic and uremic patients [24–34]. Like in the non-
sodes of hypercalcemia, improved control of intact PTH,uremic patient, calcification in ESRD occurs in the arte-
or other metabolic effects (such as, lipids) are responsiblerial intima in association with atherosclerotic plaques [35].
for the benefit. At present, it is difficult to ascribe the pro-However, medial calcification can also occur and probably
gression in calcification to vitamin D per se, since usageincreases arterial stiffness and ventricular afterload [36].
was increased in the sevelamer-treated subjects who ex-Increased arterial stiffness in turn has been associated
perienced less calcification over time.
with increased cardiovascular mortality in ESRD [33, 34]. In summary, herein we provide evidence that treat-
In observational studies, cardiovascular calcification ment with sevelamer results in fewer episodes of hyper-
in ESRD has been variably associated with age, dialysis calcemia, improved control of PTH and attenuation of
vintage, race, diabetes, serum phosphorus, calcium, HDL the progression of coronary artery and aortic calcifica-
cholesterol and triglyceride concentrations, markers of tion relative to calcium salts. It remains to be demon-
inflammation, and higher doses of calcium salts used as strated whether attenuation of coronary artery and aortic
phosphate binders [8, 11, 36–38]. However, to our knowl- calcification will translate into a reduction in the burden
of cardiovascular disease in this vulnerable population.edge this is the first study in patients with ESRD in
Chertow et al: Calcification in HD patients252
repeated coronary artery calcium measurements by electron beamACKNOWLEDGMENTS
tomography. Am J Cardiol 87:210–213, 2001
18. Schmermund A, Baumgart D, Mohlenkamp S, et al: Natural his-This study was supported by Genzyme Corporation. This work was
tory and topographic pattern of progression of coronary calcifica-presented in part at the 1st World Congress of Nephrology in San
tion in symptomatic patients: An electron-beam CT study. Arterio-Francisco, CA, October 2001. The authors are grateful to Scott Chasen-
scler Thromb Vasc Biol 21:421–426, 2001Taber, PhD for assistance in statistical analysis; Naseem Amin, MD,
19. Rumberger JA, Brundage BH, Rader DJ, Kondos G: ElectronMaureen Dillon, MA, Amy Boulay, MPH, and Jaap Heijnis, PhD, for
beam computed tomographic coronary calcium scanning: A reviewassistance in study planning and implementation; the study coordina-
of guidelines on use in asymptomatic persons. Mayo Clin Proc 74:tors and participating dialysis units for facilitation of laboratory collec-
243–252, 1999tion and EBT scheduling; and especially to the persons on maintenance
20. Callister TQ, Raggi P, Cooil B, et al: Effect of HMG-CoAdialysis who gave graciously of their time, energy, and spirit on behalf
reductase inhibitors on coronary artery disease as assessed by elec-of the study.
tron-beam computed tomography. N Engl J Med 339:1972–1978, 1998
21. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-Reprint requests to Paolo Raggi, M.D., Department of Medicine,
term effects of sevelamer hydrochloride on the calcium x phosphateTulane University School of Medicine, 1430 Tulane Avenue, SL48 New
product and lipid profile of haemodialysis patients. Nephrol DialOrleans, Louisiana 70112, USA.
Transplant 14:2907–2914, 1999E-mail: praggi@tulane.edu
22. Bleyer AJ, Burke SK, Dillon M, Garrett B: A comparison of
the calcium-free phosphate binder sevelamer hydrochloride with
calcium acetate in the treatment of hyperphosphatemia in hemo-REFERENCES
dialysis patients. Am J Kidney Dis 33:694–701, 1999
1. US Renal Data System: USRDS 2000 Annual Report. Bethesda, 23. Chertow GM, Dillon MA, Amin N, Burke SK: Sevelamer with
National Institutes of Health, National Institute of Diabetes and and without calcium and vitamin D: observations from a long-term
Digestive and Kidney Diseases, 2000 open-label clinical trial. J Ren Nutr 10:125–132, 2000
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of car- 24. Raggi P, Callister TQ, Cooil B, et al: Identification of patients
diovascular disease in chronic renal disease. Am J Kidney Dis 32 at increased risk of first unheralded acute myocardial infarc-
(Suppl 3):S112–S119, 1998 tion by electron beam computed tomography. Circulation 101:850–
3. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing 855, 2000
the cardiac risk profile in chronic hemodialysis patients: A hypothe- 25. Simons DB, Schwartz RS, Edwards WD, et al: Noninvasive defi-
sis on the role of oxidant stress and other non-traditional risk nition of anatomic coronary artery disease by ultrafast computed
factors. J Am Soc Nephrol 8:475–486, 1997 tomographic scanning: A quantitative pathologic comparison study.
4. Oda H, Keane WF: Lipid abnormalities in end-stage renal disease. J Am Coll Cardiol 20:1118–1126, 1992
Nephrol Dial Transplant 13:45–49, 1998 26. Sangiorgi G, Rumberger JA, Severson A, et al: Arterial calcifica-
5. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage re- tion and not lumen stenosis is highly correlated with atherosclerotic
plaque burden in humans: A histologic study of 723 coronary arterynal disease: prevalence, etiology, and potential relationship to arte-
segments using non-decalcifying methodology. Electron beam com-riosclerotic outcomes. Kidney Int 52:10–20, 1997
puted tomography and coronary artery disease: scanning for coro-6. Nishizawa Y, Shoji T, Kawagishi T, Morii H: Atherosclerosis
nary artery calcification. J Am Coll Cardiol 31:126–133, 1998in uremia: Possible roles of hyperparathyroidism and intermedi-
27. Mautner SL, Mautner GC, Froehlich J, et al: Coronary arteryate density lipoprotein accumulation. Kidney Int 52(Suppl 62):S90–
disease: Prediction with in vitro electron beam CT. Radiology 192:S92, 1997
625–630, 19947. US Renal Data System: Medication use among dialysis patients in
28. Arad Y, Spadaro LA, Goodman K, et al: Prediction of coronarythe DMMS (chapt IV), in USRDS 1998 Annual Report, Bethesda,
events with electron beam computed tomography. J Am Coll Car-National Institutes of Health, National Institute of Diabetes and
diol 36:1253–1260, 2000Digestive and Kidney Diseases, 1998
29. Wong ND, Hsu JC, Detrano RC, et al: Coronary artery calcium8. Raggi P, Boulay A, Chasan-Taber S, et al: Cardiac calcification
evaluation by electron beam computed tomography and its relationin adult hemodialysis patients: A link between ESRD and cardio-
to new cardiovascular events. Am J Cardiol 86:495–498, 2000vascular disease? J Am Coll Cardiol (in press)
30. Margolis JR, Chen JT, Kong Y, et al: The diagnostic and prognos-9. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The
tic significance of coronary artery calcification. A report of 800predictive value of commonly measured variables and an evalua-
cases. Radiology 137:609–616, 1980tion of death rate differences between facilities. Am J Kidney Dis
31. Detrano RC, Hsiai T, Wang S, et al: Prognostic value of coronary15:458–482, 1990
calcification and angiographic stenoses in patients undergoing cor-10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Associa-
onary angiography. J Am Coll Cardiol 27:285–290, 1996tion of serum phosphorus and calcium x phosphate product with
32. Raggi P, Cooil B, Callister TQ: Use of electron beam tomogra-mortality risk in chronic hemodialysis patients: A national study.
phy data to develop models for prediction of hard coronary events.Am J Kidney Dis 31:601–617, 1998
Am Heart J 141:375–382, 200111. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calci- 33. Blacher J, Guerin AP, Pannier B, et al: Impact of aortic stiff-fication in young adults with end-stage renal disease who are under- ness on survival in end-stage renal disease. Circulation 99:2434–going dialysis. N Engl J Med 342:1478–1483, 2000 2439, 1999
12. Slatopolsky E, Finch J, Clay P, et al: A novel mechanism for 34. Gue´rin AP, Blacher J, Pannier B, et al: Impact of aortic stiffness
skeletal resistance in uremia. Kidney Int 58:753–761, 2000 attenuation on survival of patients in end-stage renal failure. Cir-
13. Friedewald W, Levy R, Fredrickson D: Estimation of the concen- culation 103:987–992, 2001
tration of low density lipoprotein cholesterol in plasma, without 35. Schwarz U, Buzello M, Ritz E, Stein G: Morphology of coronary
use of the preparative ultracentrifuge. Clin Chem 18:499–502, 1972 atherosclerotic lesions in patients with end-stage renal failure.
14. Nauck M, Kramer-Guth A, Bartens W, et al: Is the determination Nephrol Dial Transplant 15:218–223, 2000
of LDL cholesterol according to Friedewald accurate in CAPD 36. Gue´rin AP, London GM, Marchais SJ, Metvier F: Arterial stiff-
and HD patients? Clin Nephrol 46:319–325, 1996 ening and vascular calcifications in end-stage renal disease. Nephrol
15. Agatston AS, Janowitz WR, Hildner FJ, et al: Quantification Dial Transplant 15:1014–1021, 2000
of coronary artery calcium using ultrafast computed tomography. 37. Braun J, Oldendorf M, Moshage W, et al: Electron beam com-
J Am Coll Cardiol 15:827–832, 1990 puted tomography in the evaluation of cardiac calcification in chronic
16. Callister TQ, Cooil B, Raya SP, et al: Coronary artery disease: dialysis patients. Am J Kidney Dis 27:394–401, 1996
Improved reproducibility of calcium scoring with an electron-beam 38. Kimura K, Saika Y, Otani H, et al: Factors associated with calcifi-
CT volumetric method. Radiology 208:807–814, 1998 cation of the abdominal aorta in hemodialysis patients. Kidney Int
56(Suppl 71):S238–S241, 199917. Achenbach S, Ropers D, Mohlenkamp S, et al: Variability of
